Catalyst Biosciences Expands its Protease Medicines Patent Portfolio of Complement Factor 3 Degraders
April 12 2021 - 8:00AM
Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the
United States Patent and Trademark Office (USPTO) has issued U.S.
Patent Number 10,954,501 B2 entitled “Nucleic Acid Encoding
Modified Membrane Type Serine Protease 1 (MTSP-1) Polypeptides and
Methods of Use." This patent expands the Company's portfolio of
intellectual property covering its complement programs and protease
medicines. The patent protects nucleic acids encoding modified
proteases that selectively cleave and degrade complement factor 3
(C3), including the lead candidate CB 2782-PEG, Catalyst's
potential best-in-class treatment for dry AMD, currently licensed
to Biogen. Further coverage of a broad range of additional uses in
diseases mediated by complement activation provides protection
until at least 2038.
"Building a strong patent intellectual property estate around
our protease medicines and complement programs protects our ability
to develop multiple assets and create long-term shareholder value,"
said Nassim Usman, Ph.D., president and chief executive officer of
Catalyst Biosciences. "We intend to continue to expand our IP as we
develop our pipeline of protease medicines."
About Catalyst Biosciences, the Protease
Medicines companyCatalyst is a research and clinical
development biopharmaceutical company focused on addressing unmet
medical needs in rare disorders of the complement and coagulation
systems. Our protease engineering platform has generated two
late-stage clinical programs, including MarzAA, a subcutaneously
(SQ) administered next-generation engineered coagulation Factor
VIIa (FVIIa) for the treatment of episodic bleeding in subjects
with rare bleeding disorders. Our complement pipeline includes a
pre-clinical C3-degrader program licensed to Biogen for dry
age-related macular degeneration, an improved complement factor I
protease for SQ replacement therapy in patients with CFI
deficiency, and C4b-degraders designed to target disorders of the
classical complement pathway as well as other complement programs
in development.
Forward-Looking StatementsThis
press release contains forward-looking statements that involve
substantial risks and uncertainties. Forward-looking statements
include statements about the protection afforded by Catalyst's
issued patents, the potential uses and benefits of products based
on Catalyst's engineered protease platform, and the Company's
collaboration with Biogen for the development and commercialization
of a pre-clinical C3-degrader program for the potential treatment
of dry age-related macular degeneration. Actual results or events
could differ materially from the plans, intentions, expectations
and projections disclosed in the forward-looking statements.
Various important factors could cause actual results or events to
differ materially, including, but not limited to, the risk that our
patents may be held invalid or unenforceable, that trials and
studies may be delayed as a result of COVID-19, competitive
products and other factors, that trials may not have satisfactory
outcomes, that additional human trials will not replicate the
results from earlier trials, that potential adverse effects may
arise from the testing or use of MarzAA, including the generation
of neutralizing antibodies, the risk that costs required to develop
or manufacture the Company's products will be higher than
anticipated, including as a result of delays in trial enrollment,
development and manufacturing resulting from COVID-19 and other
factors, the risk that Biogen will terminate Catalyst's agreement,
competition and other risks described in the "Risk Factors" section
of the Company's Annual Report on Form 10-K filed with
the Securities and Exchange Commission on March 4,
2021, and in other filings with the Securities and Exchange
Commission. The Company does not assume any obligation to update
any forward-looking statements, except as required by law.
Contact:Ana KaporCatalyst
Biosciences, Inc.investors@catbio.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024